title: Acceptable changes in quality attributes of glycosylated biopharmaceuticals.
authors.forename: Martin
authors.initials: M
authors.lastname: Schiestl
authors.forename: Thomas
authors.initials: T
authors.lastname: Stangler
authors.forename: Claudia
authors.initials: C
authors.lastname: Torella
authors.forename: Tadej
authors.initials: T
authors.lastname: Cepeljnik
authors.forename: Hansjörg
authors.initials: H
authors.lastname: Toll
authors.forename: Roger
authors.initials: R
authors.lastname: Grau
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology; D001688:Biological Products / Q000592:standards*; D020811:Biomedical Technology / Q000592:standards*; D001702:Biopharmaceutics / Q000592:standards*; D055598:Chemical Phenomena; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000592:standards; D005062:European Union; D006031:Glycosylation; D006801:Humans; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001688:Biological Products; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000069283:Rituximab